So far this year, investment in artificial intelligence (AI) data centres has contributed more to US economic growth than all consumer spending combined. Even if there is still some scepticism about ...

Investors Chronicle provides share tips, stock market data and analysis, as well as beginners’ guides on how to invest in shares and the stock market. We cover most UK companies’ financial results, ...

Our reader has substantial savings but wonders if focusing on income is holding him back. Dave Baxter finds out ...

One company worth examining is Equinix (US:EQIX), a California-based multinational that specialises in internet connectivity and co-location centres. It essentially offers space within data centres, ...

As results season winds down, Dan Jones and team discuss a property group’s results, alternative ways to find bargain stocks and Novo Nordisk vs Eli Lilly ...

The FTSE 100 hit 9,200 as mining stocks took up the baton and ran on Friday morning following a third straight record close on Wall Street. Glencore, Antofagasta and Anglo American all rose 2-3 per ...

CPI inflation rose more than expected in the last reading, to 3.6 per cent in June. The MPC now thinks price growth will peak at 4 per cent in September, driven higher by food prices.

Investors Chronicle provides share tips, stock market data and analysis, as well as beginners’ guides on how to invest in shares and the stock market. We cover most UK companies’ financial results, ...

Copper miner Antofagasta (ANTO) revved up its interim profits through higher gold and copper production, resulting in a mid-year payout twice that of last year. The cash profit was $2.2bn (£1.6bn), ...

Investors Chronicle provides share tips, stock market data and analysis, as well as beginners’ guides on how to invest in shares and the stock market. We cover most UK companies’ financial results, ...

Investors Chronicle provides share tips, stock market data and analysis, as well as beginners’ guides on how to invest in shares and the stock market. We cover most UK companies’ financial results, ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...